Press Release
Press Release
Press Contacts: Erik Cummins, Matt Hyams, Taina Rosa, Olivia Thomas
02.19.25
Pillsbury advised U.S.-based biopharmaceutical company Sentynl Therapeutics, Inc. in its acquisition of Eiger Biopharmaceutical’s Zokinvy® (lonafarnib) program garnering the Distressed M&A Deal of the Year at the 16th Annual Americas M&A Atlas Awards Gala. The awards, which were revealed on February 6 in New York City, recognize the top value-creating deals, exceptional firms and iconic dealmakers from the corporate, investor and transactional communities of North and Latin America.
Sentynl’s acquisition of Zokinvy, the first and only treatment approved by the U.S. Food and Drug Administration to target the cause and symptoms of progeria, was conducted through a chapter 11 sale process where Sentynl served as the “stalking horse bidder” and ultimately prevailed in a competitive auction process. As such, under the agreement, Sentynl acquired the global rights to Zokinvy and was given responsibility for its manufacturing and commercialization. Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS), and processing-deficient progeroid laminopathies (PDPL) in young people 12 months of age and older.
To learn more about the acquisition, click here.
The Pillsbury deal team was led by Life Sciences Corporate partner Jason Stirling and Insolvency & Restructuring partner Joshua Morse and included Insolvency & Restructuring partner Rahman Connelly and associate James Dickinson and Tax partner Brett Willis.
Corporate partner Christian Salaman’s longstanding relationship with Sentynl has resulted in Pillsbury advising Sentynl on acquisitions of key assets for the Sentynl portfolio. To learn more about Pillsbury’s previous transactional advice for Sentynl, click here, here and here.